Medulloblastoma: evaluation of proliferative index by monoclonal antibody Mib-1, its prognostic correlation and therapeutic implications

Ferrari, Antonio Fernandes; Araújo, Maria Betânia Mahler; Aguiar, Paulo Henrique Pires de; Plese, José Píndaro Pereira

doi:10.1590/s0004-282x2003000400004

Cited by 8 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was no statistically significant correlation between outcome and p53 ( P = 0.368) and Ki-67 ( P = 0.165) levels at 6 months. However, many previous studies done on neuroectodermal tumors by Jadali et al .,[ 29 ] Meurer et al .,[ 30 ] Ferrari et al .,[ 31 ] Nam et al .,[ 32 ] and Jaros et al . [ 7 ] have suggested the role of p53 and ki-67 as negative prognostic factors.…”

Section: Discussionmentioning

confidence: 99%

P53 and Ki-67 expression in primary pediatric brain tumors: Does it correlate with presentation, histological grade, and outcome?

et al. 2018

View full text Add to dashboard Cite

Context:Pediatric brain tumors are a vexing problem for the neurosurgeon due to the fragile patient cohort. We attempt to find parameters which can help us to treat and prognosticate these patients in a better way.Aims:This study aims to correlate clinical presentation, outcome, and histological grade with P53 and Ki-67 expression in primary pediatric brain tumors.Setting Design:This was a prospective, observational study.Patients and Methods:Forty-seven patients with primary brain tumors in the age group 0–18 years were included in this study. Clinical presentation was noted. Patients were operated, and specimen was sent for histopathological and immunohistochemistry examination for p53 and Ki-67. The WHO classification of 2007 was used to grade the tumors. Follow-up was done at 3 and 6 months with Glasgow outcome score. Expression of p53 and Ki-67 in different tumors was correlated with clinical presentation, tumor grade and outcome.Analysis Method:Statistical Package for Social Science version 17. P < 0.05 was considered statistically significant.Results:There was statistically significant correlation between high tumor grade and high Ki-67 levels (P = 0.000). On post hoc analysis, there was a significant difference between p53 levels in Grade 1 and Grade 4 tumors. There was statistically significant correlation between neurological deficit and higher p53 levels (P = 0.040). There was statistically significant correlation between poor outcome and higher p53 (P = 0.034) and Ki-67 (P = 0.000) levels at 3 months follow-up which continued at 6 months.Conclusions:From this study, we conclude that p53 and Ki-67 expression in pediatric brain tumors is associated with poor outcome and correlates with tumor grade. Moreover, p53 expression correlates with neurological deficit.

show abstract

Section: Discussionmentioning

confidence: 99%

P53 and Ki-67 expression in primary pediatric brain tumors: Does it correlate with presentation, histological grade, and outcome?

et al. 2018

View full text Add to dashboard Cite

show abstract

“…For non-functioning pituitary adenomas promising data exist to support an inverse correlation of Ki67 tumor cell proliferation index with time to progression [30, 31, 32]. With regard to the prognostic value of Ki67 tumor cell proliferation index, only small studies or conflicting results exist for oligodendroglial tumors, diffuse astrocytomas, meningiomas and medulloblastomas [24, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44]. Several studies indicate that the Ki67 tumor cell proliferation index has no prognostic value in glioblastomas [36, 38, 45].…”

Section: Ki67 Tumor Cell Proliferation Indexmentioning

confidence: 99%

Clinical Neuropathology Practice Guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers

Berghoff¹,

Stefanits²,

Wöehrer³

et al. 2013

View full text Add to dashboard Cite

A large number of potential tissue biomarkers has been proposed for brain tumors. However, hardly any have been adopted for routine clinical use, so far. For most candidate biomarkers substantial controversy exists with regard to their usefulness in clinical practice. The multidisciplinary neurooncology taskforce of the Vienna Comprehensive Cancer Center Central Nervous System Unit (CCC-CNS) addressed this issue and elaborated a four-tiered levels-of-evidence system for assessing analytical performance (reliability of test result) and clinical performance (prognostic or predictive) based on consensually defined criteria. The taskforce also consensually agreed that only biomarker candidates should be considered as ready for clinical use, which meet defined quality standards for both, analytical and clinical performance. Applying this levels-of-evidence system to MGMT, IDH1, 1p19q, Ki67, MYCC, MYCN and β-catenin, only immunohistochemical IDH1 mutation testing in patients with diffuse gliomas is supported by sufficient evidence in order to be unequivocally qualified for clinical use. For the other candidate biomarkers lack of published evidence of sufficiently high analytical test performance and, in some cases, also of clinical performance limits evidence-based confirmation of their clinical utility. For most of the markers, no common standard of laboratory testing exists. We conclude that, at present, there is a strong need for studies that specifically address the analytical performance of candidate brain tumor biomarkers. In addition, standardization of laboratory testing is needed. We aim to regularly challenge and update the present classification in order to systematically clarify the current translational status of candidate brain tumor biomarkers and to identify specific research needs for accelerating the translational pace.

show abstract

“…MBs are rapidly proliferating tumors, and they have a quite elevated Ki-67 expression 7,15,[19][20][21] . In our study, the mean number of Ki-67-positive cells was 27.05%.…”

Section: Fig 2 Photomicrographs Of Medulloblastoma (A) Immunoreactimentioning

confidence: 99%

Immunohistochemical expression of markers Ki-67, neun, synaptophysin, p53 and HER2 in medulloblastoma and its correlation with clinicopathological parameters

Meurer

Martins

Hilbig

et al. 2008

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

-Medulloblastoma (MB) is the most common malignant brain tumor in childhood. The alterations found include: presence of oncoproteins p53 and HER2, elevated mitotic index, and presence of neuronal differentiation. The aim of this study was to determine the immunohistochemical expression of markers Ki-67, NeuN, synaptophysin, HER2 and p53 in 40 MB samples and their correlation with clinicopathologic parameters and survival. In 29 patients (72.5%), ≥20% of cells were positive for Ki-67. Males showed greater ki-67 expression (p=0.02) and smaller survival rates (p=0.002). NeuN and synaptophysin were negative in 16 (40%) and 8 (20%) cases, respectively. P53 was positive in 18 (45%) cases, with 11 (61%) weakly positive and 7 (39%) strongly positive. HER2 was positive in 23 (57.5%) of the samples and did not show statistical association with survival (p=0.07).KEy woRds: medulloblastoma, immunohistochemistry, Ki-67, NeuN, synaptophysin, HER2, p53, survival analysis. expressão imunoistoquímica dos marcadores ki-67, neun, sinaptofisina, p53 e her2 em meduloblastoma e sua correlação com os parâmetros clínico-patológicosResumo -Meduloblastoma (MB) é o tumor maligno encefálico mais freqüente na infância. dentre as alterações encontradas estão: a presença das oncoproteínas p53 e HER2, elevado índice mitótico e presença de diferenciação neuronal. o objetivo deste estudo foi determinar a expressão imunoistoquímica (IMQ) dos marcadores Ki-67, NeuN, sinaptofisina, HER2 e p53 em 40 amostras de MB, correlacionando-as com parâmetros clinicopatológicos e com a sobrevida. Vinte e nove pacientes (72,5%) apresentaram 20% ou mais das células positivas para Ki-67. os pacientes do sexo masculino apresentaram maior expressão do Ki-67 (p=0,02) e também menor sobrevida (p=0,002). NeuN e sinaptofisina foram negativos em 16 (40%) e 8 (20%) casos, respectivamente. P53 foi positivo em 18 (45%) casos, sendo 11 (61%) fracamente positivos e 7 (39%) fortemente positivos. HER2 foi positivo em 23 (57,5%) das amostras e não demonstrou associação estatística com a sobrevida (p=0.07).PAlAVRAs-cHAVE: meduloblastoma, imunoistoquímica, Ki-67, NeuN, sinaptofisina, HER2, p53, sobrevida. Medulloblastoma (MB) is the most common malignant brain tumor in children, accounting for about 20% of all primary tumors of the central nervous system (cNs), with a peak of incidence at 5-7 years-old. These tumors have an aggressive behavior and despite treatment, the 5-year survival rate is 60% 1,2 . For therapeutic and prognostic purposes, patients are divided in groups of high and low risk, according to the staging proposed by chang et al. (1969) 3 , age at the time of diagnosis, and presence of residual tumor 4,5 . A more accurate assessment of risk in children with MB can be done using a combination of clinical, histopathologic, and molecular prognostic factors 4,6,7 .

show abstract

Medulloblastoma: evaluation of proliferative index by monoclonal antibody Mib-1, its prognostic correlation and therapeutic implications

Cited by 8 publications

References 13 publications

P53 and Ki-67 expression in primary pediatric brain tumors: Does it correlate with presentation, histological grade, and outcome?

P53 and Ki-67 expression in primary pediatric brain tumors: Does it correlate with presentation, histological grade, and outcome?

Clinical Neuropathology Practice Guide 3-2013: levels of evidence and clinical utility of prognostic and predictive candidate brain tumor biomarkers

Immunohistochemical expression of markers Ki-67, neun, synaptophysin, p53 and HER2 in medulloblastoma and its correlation with clinicopathological parameters

Contact Info

Product

Resources

About